Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      CureGene Presents Two Preclinical Studies of CG-0416 at Obesity Week 2026


      News provided by

      CureGene

      Nov 15, 2026, 23:15 ET

      Share this article

      Share this article


      CG-0416 combined with a reduced-dose GLP-1 receptor agonist produced greater weight loss, and slower weight regain after the agonist was stopped

      SHANGHAI, Nov. 15, 2026 /PRNewswire/ -- In a poster at Obesity Week 2026, CureGene presented two preclinical studies of CG-0416, its oral, liver-targeted thyroid hormone receptor beta (THR-β) agonist. Both address questions clinicians raise in practice: whether combining CG-0416 with a GLP-1 receptor agonist can deliver more weight loss at a lower agonist dose, and whether CG-0416 alone can sustain the benefit once the agonist is stopped.

      Both studies were conducted in diet-induced obese (DIO) mice. CG-0416 given with a reduced dose of a GLP-1 receptor agonist produced greater weight loss than the full agonist dose alone. Continuing CG-0416 after the agonist was withdrawn slowed weight regain markedly.

      Poster-208 | Saturday, November 14, 2026, 7:30 – 8:30 PM ET | Washington, DC

      Losing Weight Is Only Half the Job

      GLP-1 receptor agonists have taken weight loss to a new level. As they enter broad clinical use, two questions have become urgent: how to get more weight loss at a lower dose and with fewer side effects, and how to hold on to the result once treatment stops. CG-0416 works differently. It does not act on appetite centers in the brain. It is a liver-targeted hydrolysis prodrug: a single esterase step releases its active metabolite in the liver, where it activates THR-β, drives fat breakdown and raises thermogenesis. Because it works peripherally rather than centrally, it can be used alone or alongside a GLP-1 receptor agonist.

      Combination: More Weight Loss at a Lower GLP-1 Receptor Agonist Dose

      The combination study compared a GLP-1 receptor agonist alone with the same agonist plus CG-0416. At the reduced agonist dose, the combination produced a 35.2% reduction in body weight, versus 7.6% with the full agonist dose alone. That is roughly a 3.6-fold difference, and it points to synergy.

      These results suggest CG-0416 may allow a lower GLP-1 receptor agonist dose without sacrificing efficacy. That would mean fewer titration steps, fewer class-related side effects and better muscle preservation. Food intake did not rise with the combination, suggesting the extra weight loss did not come from eating less.

      After Discontinuation: Continuing CG-0416 Slowed Weight Regain

      The maintenance study was designed to mirror real-world use. Mice received CG-0416 plus a GLP-1 receptor agonist first; the agonist was then stopped and CG-0416 continued alone.

      Compared with control, the CG-0416 group regained about 38% less weight in this model. Lean mass (muscle, organs and water, excluding fat) was better preserved, roughly 10% above control, and fat mass was 12.1% lower. No side effects typical of GLP-1 receptor agonists were seen.

      For long-term treatment, these data address a different question. Getting weight down is only the first step. Keeping it off after treatment stops is what determines long-term success.

      Three Potential Uses: Monotherapy, Combination and Sequential Maintenance

      Monotherapy would target patients whose priority is fat loss with muscle preservation. Combination therapy would target patients with overweight or obesity who need greater weight loss, and allow a lower agonist dose without loss of efficacy. Sequential maintenance covers the period after a GLP-1 receptor agonist is stopped, to slow regain and protect lean mass.

      Together, the three uses point to one conclusion: weight management has to be sustained, not treated as a sprint. CG-0416 was designed on CureGene's proprietary A-ProX platform, which uses a single esterase hydrolysis step to release the active metabolite and direct it to the liver. Phase I trials are under way in Australia, and a Phase I trial in China will start shortly.

      About Obesity Week 2026

      Obesity Week, organized by The Obesity Society (TOS), is the largest international meeting on obesity, covering causes, prevention, pharmacotherapy, bariatric surgery and lifestyle intervention. The 2026 meeting runs November 14–17 in Washington, DC, and is expected to draw more than 4,300 professionals from over 60 countries, with more than 700 research posters.

      About CG-0416

      CG-0416 is a novel thyroid hormone receptor beta (THR-β) agonist that CureGene designed as a liver-targeted hydrolysis prodrug. A single esterase hydrolysis step releases the active metabolite, which acts selectively in the liver: it promotes breakdown of white adipose tissue and upregulates the thermogenic gene UCP-1, lowering liver fat and improving lipids and glucose tolerance. In preclinical studies, CG-0416 alone caused minimal muscle loss in DIO mice and was not associated with side effects typical of GLP-1 receptor agonists; with a GLP-1 receptor agonist it acted synergistically. Phase I trials are under way in Australia, and a Phase I trial in China will start shortly.

      For more information on the CG-0416 program, visit the CureGene website at www.curegene.com.cn.

      About the A-ProX Platform

      A-ProX is CureGene's AI-enabled prodrug platform, a programmable system for delivering drugs to multiple organs. Conventional prodrugs depend on a single metabolic route in the liver; A-ProX instead tailors the prodrug to the physiology of the liver and of other tissues, so the active ingredient concentrates in the target organ and stays there longer. The result is higher efficacy at lower systemic exposure. Both CG-0416 and Evategrel were designed on this platform.

      About CureGene Pharmaceutical

      Founded in 2018, CureGene Pharmaceutical possesses proprietary core platform technologies and independent high-efficiency innovation capabilities. The Company primarily focuses on therapeutic areas including cardiovascular & cerebrovascular diseases and antiviral therapies, striving to become a China-rooted, globally oriented innovative pharmaceutical enterprise.
      Leveraging its proprietary platforms, CureGene has built a robust pipeline of innovative assets with broad market value and global independent intellectual property rights, with multiple candidates actively progressing through clinical development. Driven by its corporate mission and vision, the Company has assembled a high-caliber team of globally minded scientists and overseas returnees. Under its integrated strategic layout, CureGene achieves rapid and efficient R&D translation, with all pipeline candidates demonstrating strong potential to become first-in-class or best-in-class therapies.

      Forward-Looking Statement

      The information released in this press release may contain certain forward-looking statements (such as "will", "anticipate", "forecast", "expect", "intend", "plan", "believe", "estimate", "be confident" and other similar expressions), which are based on the current views, beliefs and expectations that the Company or its management has towards the Company's business operations and financial performance when such statements are made. These forward-looking statements shall not be deemed as guarantees of future outcomes, and such outcomes may be affected by risks, uncertainties, and other factors, some of which are beyond the Company's control and difficult to predict. Therefore, subject to the impacts of our business, general industry conditions and competition, environment, politics, general economic factors (including fluctuations in interest rates and exchange rates), pharmaceutical industry regulations and medical policies, technological developments, new products and patents obtained by any competitors, the inherent challenges in new product development (including obtaining regulatory approvals), production difficulties or delays, instability in the international economic and financial situation and sovereign risks, reliance on the effectiveness of the protection of the Company's patents and other innovative products, the Company's risks of facing patent litigation and/or regulatory actions, future changes and developments in social situations and other various factors and assumptions, the actual results may differ significantly from the information contained in the forward-looking statements.

      Such forward-looking statements shall not in any way be considered as any commitments/guarantee made by the Company, its subsidiaries, or any of its directors, officers, management personnel, advisors, employees and/or agents regarding relevant matters. They do not constitute a recommendation to engage in a certain act. None of such personnel assumes any liability with respect to such forward-looking statements. Moreover, the Company and its subsidiaries, directors, management personnel, consultants, employees and/or agents have not and will not assume any responsibility for updating the forward-looking statements contained in this press release to reflect the latest information, future projects or circumstances or events that occur after the release date.

      BD and Media Contact

      BD: [email protected]

      SOURCE CureGene

      Modal title

      Also from this source

      Timing Affects Speed, Not Total Exposure

      Clopidogrel does not work the same way in every patient. In East Asian populations the gap is wider still: a share of patients get too little...

      CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist

      CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      Trade Show News

      Trade Show News

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.